Generalized Anxiety Disorder (GAD)- Market Insight, Epidemiology and Market Forecast -2030

DelveInsight’s ‘Generalized Anxiety Disorder (GAD)-Market Insights, Epidemiology and Market Forecast—2030’ report delivers an in-depth understanding of the GAD, historical and forecasted epidemiology as well as the GAD market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom), and Japan.

The GAD market report provides current treatment practices, emerging drugs, GAD market share of the individual therapies, current and forecasted GAD market size from 2017 to 2030 segmented by seven major markets. The Report also covers current GAD treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses underlying potential of the market.

Geography Covered
• The United States
• EU5 (Germany, France, Italy, Spain and the United Kingdom)
• Japan

Study Period: 2017–2030
Generalized Anxiety Disorder (GAD): Disease Understanding and Treatment Algorithm
Generalized Anxiety Disorder Overview
Generalized Anxiety Disorder (GAD) is characterized by persistent and exaggerated anxiety and worry about everyday life events with no obvious reasons for worry. People with GAD may anticipate disaster and may be overly concerned about money, health, family, work, or other issues. Individuals with GAD find it difficult to control their worry. They may worry more than seems warranted about actual events or may expect the worst even when there is no apparent reason for concern. According to Anxiety and Depression Association of America (ADAA), GAD affects around 6.8 million adults or 3.1% of the US adult population in any given year and the criteria used for diagnosis was based on DSM-IV. However, latest DSM-V yielded an influx of new GAD cases which give rise to the prevalence rate as well in adult population (i.e. 12-month prevalence rate is 4% in the US adult population). Women are twice as likely to be affected. GAD can begin at any point in the life cycle but usually develops between childhood and middle age. People with GAD experience a combination of emotional, behavioral, and physical symptoms that often fluctuate, becoming worse at times of stress. The anxiety is often associated with physical symptoms, such as sleep disturbance, restlessness, muscle tension, gastrointestinal symptoms, and chronic headaches and others. It also includes several psychological symptoms.

Generalized Anxiety Disorder Diagnosis
GAD is diagnosed when a person finds it difficult to control worry on more days than not for at least 6 months. An evaluation of symptom criteria, as outlined in DSM-5, is the first step for diagnosis followed by physical exam, blood tests, urine tests, gastric reflux tests, such as an X-ray of the digestive system or an endoscopy procedure to look at the esophagus, and stress tests.

Generalized Anxiety Disorder Treatment
• Treatment prescribed by the doctor depends on many factors, including symptoms intensity and duration, impact on the patient’s ability to function in daily life, comorbid conditions such as depression, and medical conditions. Patients with mild anxiety and worry who do not meet the DSM-V criteria for GAD often benefit from supportive therapy and encouragement.
• The standard category of pharmacological agents used in the management of GAD includes Selective serotonin re-uptake inhibitors (SSRIs), Selective norepinephrine reuptake inhibitors (SNRIs), Pregabalin, Tricyclic antidepressants (TCAs), Benzodiazepines, Antihistamines, Atypical antipsychotics, Antioxidants, and others
• SSRIs and SNRIs (Citalopram, Escitalopram, Fluoxetine, Paroxetine, Sertraline, Duloxetine, Venlafaxine XR etc.) and buspirone are considered as first treatment strategy.

Generalized Anxiety Disorder (GAD) Epidemiology
The GAD epidemiology division provides the insights about historical and current GAD patient pool and forecasted trend for each seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings
The disease epidemiology covered in the report provides historical as well as forecasted GAD epidemiology [segmented as Total12-Month Prevalent Cases of Generalized Anxiety Disorder in 7MM (Adult, Adolescents and Children),Gender-Specific Prevalence of Generalized Anxiety Disorder in 7MM,Age-Specific Prevalence of Generalized Anxiety Disorder, Severity-Specific Prevalence of Generalized Anxiety Disorder] scenario of GAD in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2017 to 2030.

Country Wise-Generalized Anxiety Disorder Epidemiology
• The Total 12-Month Prevalent Cases of GAD in 7MM was 16,606,987 in 2017, based on DSM-V criteria. Estimates show that the United States accounted for the highest number of cases of GAD among all the 7MM countries, i.e., 11,113,727. Among the EU5, France has the highest prevalence with estimated 1,304,965 cases in 2017.
• In 2017, there were a total of 4,083,434 cases of GAD in the age-group (18–24), and 685,341 cases in 65 and above, in the United States.
• The severity of GAD Is divided into mild, moderate, or severe based on the number of criteria symptoms such as a functional disability in work role performance, household maintenance, social life, and intimate relationships with the severity of the symptoms.
• In 2017, there were 238,201 mild cases, 459,904 moderate cases and 333,070 severe cases of GAD in the US. The overall children and adolescent specific severity specific cases of GAD are subjected to increase in the coming years.

Generalized Anxiety Disorder Drug Chapters
Drug chapter segment of the Generalized Anxiety Disorder report encloses the detailed analysis of Generalized Anxiety Disorder marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Generalized Anxiety Disorder clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Generalized Anxiety Disorder Emerging Drugs
Troriluzole: BioHaven Pharmaceuticals
Troriluzole is a third-generation pro drug and new chemical entity that modulates glutamate, the most abundant excitatory neurotransmitter in the human body. The primary mode of action of troriluzole is reducing synaptic levels of glutamate. Troriluzole monotherapy at 100mg twice daily did not differentiate from placebo on the primary endpoint of the mean change from baseline on the Hamilton Anxiety Rating Scale (HAM-A) after eight weeks of treatment.

BNC210: Bionomics
Bionomics' first in class small molecule BNC210, is a negative allosteric modulator of the α7 nicotinic acetylcholine receptor in development for the treatment of anxiety disorders, co-morbid anxiety and depression. Single doses of BNC210 have been evaluated in GAD patients in a fMRI study with the emotional faces task, and a behavioral study with the joystick operated runway task.

PH94B: Pherin Pharmaceuticals/VistaGen Therapeutics
VistaGen’s PH94B neuroactive nasal spray is fundamentally different from all current drug treatments for GAD. PH94B binds to nasal chemosensory receptors which activate neural circuits that lead to rapid suppression of fear and anxiety. With its novel mechanism of pharmacological action, rapid-onset of therapeutic effects and exceptional safety and tolerability profile shown in clinical trials to date.

Products detail in the report…
Generalized Anxiety Disorder Market Outlook
Key Findings
According to DelveInsight, Generalized Anxiety Disorder market in the 7MM is expected to change in the study period 2017–2030.The therapeutic market of Generalized Anxiety Disorder in seven major markets was found to be USD 3,164 million in 2017which is expected to increase during study period (2017–2030).

The United States Market Outlook
In 2017, the total market size of GAD therapies was found to be USD 2,463 million in the United States which is expected to increase in the study period (2017–2030).

EU-5 Countries: Market Outlook
In 2017, the total market size of GAD therapies was found to be USD 542 million in the EU-5 countries which is expected to increase in the study period (2017–2030).

Japan Market Outlook
The total market size of GAD therapies in Japan was found to be USD 160 million in 2017.
Generalized Anxiety Disorder Pipeline Development Activities
The drugs which are in pipeline includes:
1 BNC210: Bionomics
2 PH94B: Pherin Pharmaceuticals/VistaGen Therapeutics
3 Troriluzole: BioHaven Pharmaceuticals
List is not exhaustive, full list and Products detail will be provided in the report…
Pipeline Development Activities

Key Points
1. In February 2020, Biohaven Pharmaceutical Holding Company Ltd. reported negative topline results from its Phase III clinical trial evaluating troriluzole compared to placebo for the treatment of patients with GAD.
2. In September 2018, VistaGen acquired from Pherin an exclusive worldwide license to develop and commercialize PH94B.

Generalized Anxiety Disorder Drugs Uptake
• Currently, the GAD market is mainly dominated by generics. And also generics for the most of therapies has entered in to the market. This generic nature of market creating high hurdles for approval and market access to the new drugs
Access and Reimbursement Scenario in Generalized Anxiety Disorder Therapies
• In August 2009, the Institute for Quality and Efficiency in Health Care (IQWiG) investigated whether patients with depression benefit from taking drugs belonging to the SNRI drug class. According to the report, the benefit of both drugs, venlafaxine and duloxetine were proven compared to a sham drug (placebo): patients respond better to the therapy and suffer less from the symptoms of depression.

KOL-Views
To keep up with current market trends, we take KOLs and SME’s opinion working in Generalized Anxiety Disorder domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Generalized Anxiety Disorder market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis
We perform Competitive and Market Intelligence analysis of the Generalized Anxiety Disorder Market by using various Competitive Intelligence tools that includes – SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report
• The report covers the descriptive overview of Generalized Anxiety Disorder, explaining its causes, signs and symptoms, pathophysiology and currently available therapies.
• Comprehensive insight has been provided into the Generalized Anxiety Disorder epidemiology and treatment in the 7MM.
• Additionally, an all-inclusive account of both the current and emerging therapies for Generalized Anxiety Disorder are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
• A detailed review of Generalized Anxiety Disorder market; historical and forecasted is included in the report, covering drug outreach in the 7MM.
• The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Generalized Anxiety Disorder market.

Report Highlights
• In the coming years, Generalized Anxiety Disorder market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies and academics are working to assess challenges and seek opportunities that could influence Generalized Anxiety Disorder R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
• Major players are involved in developing therapies for Generalized Anxiety Disorder. Launch of emerging therapies, will significantly impact the Generalized Anxiety Disorder market.
• A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Generalized Anxiety Disorder.
• Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Generalized Anxiety Disorder Report Insights
• Patient Population
• Therapeutic Approaches
• Generalized Anxiety Disorder Pipeline Analysis
• Generalized Anxiety Disorder Market Size and Trends
• Market Opportunities
• Impact of upcoming Therapies
Generalized Anxiety Disorder Report Key Strengths
• 11 Years Forecast
• 7MM Coverage
• Generalized Anxiety Disorder Epidemiology Segmentation
• Key Cross Competition
• Highly Analyzed Market
• Drugs Uptake
Generalized Anxiety Disorder Report Assessment
• SWOT Analysis
• Current Treatment Practices
• Unmet Needs
• Pipeline Product Profiles
• Conjoint Analysis
• Market Attractiveness
• Market Drivers and Barriers

Key Questions
Market Insights:
• What was the Generalized Anxiety Disorder Market share (%) distribution in 2017 and how it would look like in 2030?
• What would be the Generalized Anxiety Disorder total market Size as well as market size by therapies across the 7MM during the study period (2017–2030)?
• What are the key findings pertaining to the market across the 7MM and which country will have the largest Generalized Anxiety Disorder market size during the study period (2017–2030)?
• At what CAGR, the Generalized Anxiety Disorder market is expected to grow in the 7MM during the study period (2017–2030)?
• What would be the Generalized Anxiety Disorder market outlook across the 7MM during the study period (2017–2030)?
• What would be the Generalized Anxiety Disorder market growth till 2030 and what will be the resultant market size in the year 2030?
• How would the market drivers, barriers and future opportunities affect the market dynamics and a subsequent analysis of the associated trends?
• Generalized Anxiety Disorder patient types/ pool where unmet need is more and whether emerging therapies will be able to address the residual unmet need?
• How emerging therapies are performing on the parameters like efficacy, safety, route of administration (RoA), treatment duration and frequencies based on their clinical trial results?
• Among the emerging therapies, what are the potential therapies which are expected to disrupt the Generalized Anxiety Disorder market?

Epidemiology Insights:
• What is the disease risk, burden and unmet needs of the Generalized Anxiety Disorder?
• What is the historical Generalized Anxiety Disorder patient pool in seven major markets covering the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan?
• What would be the forecasted patient pool of Generalized Anxiety Disorder in 7 major markets covering the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan?
• What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Generalized Anxiety Disorder?
• Out of all the 7MM countries, which country would have the highest prevalent population of Generalized Anxiety Disorder during the study period (2017–2030)?
• At what CAGR the population is expected to grow in the 7MM during the study period (2017–2030)?
• What are the various recent and upcoming events which are expected to improve the diagnosis of Generalized Anxiety Disorder?

Current Treatment Scenario, Marketed Drugs and Emerging Therapies:
• What are the current options for the treatment of Generalized Anxiety Disorder along with the approved therapy?
• What are the current treatment guidelines for the treatment of Generalized Anxiety Disorder in the US, Europe and Japan?
• What are the Generalized Anxiety Disorder marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
• How many companies are developing therapies for the treatment of Generalized Anxiety Disorder?
• How many therapies are developed by each company for the treatment of Generalized Anxiety Disorder?
• How many emerging therapies are in mid stage, and late stage of development for the treatment of Generalized Anxiety Disorder?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Generalized Anxiety Disorder therapies?
• What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Generalized Anxiety Disorder and their status?
• What are the key designations that have been granted for the emerging therapies for Generalized Anxiety Disorder?
• What are the global historical and forecasted market of Generalized Anxiety Disorder?

Reasons to buy
• The report will help in developing business strategies by understanding trends shaping and driving the Generalized Anxiety Disorder market.
• To understand the future market competition in the Generalized Anxiety Disorder market and Insightful review of the key market drivers and barriers.
• Organize sales and marketing efforts by identifying the best opportunities for Generalized Anxiety Disorder in the US, Europe (Germany, France, Italy, Spain, and the United Kingdom) and Japan.
• Identification of strong upcoming players in market will help in devising strategies that will help in getting ahead of competitors.
• Organize sales and marketing efforts by identifying the best opportunities for Generalized Anxiety Disorder market.
• To understand the future market competition in the Generalized Anxiety Disorder market.


1. Key Insights
2. Executive Summary of Generalized Anxiety Disorder (GAD)
3. SWOT Analysis of GAD
4. Epidemiology and Market Methodology
5. GAD: Market Overview at a Glance
5.1. Total Market Share (%) Distribution of GAD in 2017
5.2. Total Market Share (%) Distribution of GAD in 2030
6. GAD: Disease Background and Overview
6.1. Introduction
6.2. Signs and Symptoms
6.3. Risk Factors and Causes
6.4. Pathophysiology
6.5. Diagnosis
6.6. Screening Tools
7. Epidemiology and Patient Population
7.1. Key Findings
7.2. Assumptions and Rationale
7.2.1. United States
7.2.2. EU5
7.2.3. Japan
7.3. Epidemiology: 7MM
7.4. Total 12-Month Prevalent Cases of GAD in 7MM
8. United States
8.1. Total 12-Month Prevalent Cases of GAD in the United States
8.2. Gender-Specific Cases of GAD in the United States
8.3. Age-Specific Cases of GAD in the United States
8.4. Severity -Specific Cases of GAD in the United States
8.4.1. Children and Adolescents
8.4.2. Adults
9. EU5
9.1. Germany
9.1.1. Total 12-Month Prevalent Cases of GAD in Germany
9.1.2. Gender-Specific Cases of GAD in Germany
9.1.3. Age-Specific Cases of GAD in Germany
9.1.4. Severity -Specific Cases of GAD in Germany
9.2. France
9.2.1. Total 12-Month Prevalent Cases of GAD in France
9.2.2. Gender-Specific Cases of GAD in France
9.2.3. Age-Specific Cases of GAD in France
9.2.4. Severity -Specific Cases of GAD in France
9.3. Italy
9.3.1. Total 12-Month Prevalent Cases of GAD in Italy
9.3.2. Gender-Specific Cases of GAD in Italy
9.3.3. Age-Specific Cases of GAD in Italy
9.3.4. Severity -Specific Cases of GAD in Italy
9.4. Spain
9.4.1. Total 12-Month Prevalent Cases of GAD in Spain
9.4.2. Gender-Specific Cases of GAD in Spain
9.4.3. Age-Specific Cases of GAD in Spain
9.4.4. Severity -Specific Cases of GAD in Spain
9.5. The United Kingdom (UK)
9.5.1. Total 12-Month Prevalent Cases of GAD in the UK
9.5.2. Gender-Specific Cases of GAD in the UK
9.5.3. Age-Specific Cases of GAD in the UK
9.5.4. Severity -Specific Cases of GAD in the UK
10. Japan
10.1. Total 12-Month Prevalent Cases of GAD in Japan
10.2. Gender-Specific Cases of GAD in Japan
10.3. Age-Specific Cases of GAD in Japan
10.4. Severity -Specific Cases of GAD in Japan
10.4.1. Children and Adolescents
10.4.2. Adults
11. Current Treatment Practices: GAD
11.1. Treatment of special populations
11.2. Treatment Guidelines
11.2.1. National Institute for Health and Care Excellence (NICE): GAD Management
11.2.2. Treatment Recommendation Summary
12. Unmet Needs
13. Case Report
13.1. A Case Report of GAD and Changes in Treatment Plan Based on Patient Care Scenario: Follow up
14. Patient Journey of GAD
15. Key Endpoints in GAD Clinical Trials
16. Marketed Therapies
16.1. Marketed Therapies Key Cross
17. Emerging Therapies
17.1. Key Cross
17.2. BNC210: Bionomics
17.2.1. Product Description
17.2.2. Other Developmental Activities
17.2.3. Safety and Efficacy
17.3. PH94B: Pherin Pharmaceuticals/VistaGen Therapeutics
17.3.1. Product Description
17.3.2. Other Developmental Activities
17.3.3. Safety and Efficacy
17.4. Intuniv (Guanfacine; previously known as SPD503): Shire (acquired by Takeda Pharmaceuticals)
17.4.1. Product Description
17.4.2. Other Developmental Activities
17.4.3. Clinical Development
17.4.4. Safety and Efficacy
17.5. Troriluzole: BioHaven Pharmaceuticals
17.5.1. Product Description
17.5.2. Other Developmental Activities
17.5.3. Clinical Development
17.5.4. Safety and Efficacy
18. GAD: Seven Major Market Analysis
18.1. Key Findings
18.2. Market Outlook: 7MM
18.3. Total Market Size of GAD in 7MM
18.4. Total Market Size of GAD by Therapies in 7MM
18.5. United States
18.5.1. Total Market size of GAD in the US
18.5.2. Total Market Size of GAD by Therapies in the US
18.6. EU5
18.7. Germany
18.7.1. Total Market size of GAD in Germany
18.7.2. Total Market Size of GAD by Therapies in Germany
18.8. France
18.8.1. Total Market size of GAD in France
18.8.2. Total Market Size of GAD by Therapies in France
18.9. Italy
18.9.1. Total Market size of GAD in Italy
18.9.2. Total Market Size of GAD by Therapies in Italy
18.10. Spain
18.10.1. Total Market size of GAD in Spain
18.10.2. Total Market Size of GAD by Therapies in Spain
18.11. United Kingdom
18.11.1. Total Market size of GAD in the UK
18.11.2. Total Market Size of GAD by Therapies in the UK
18.12. Japan
18.12.1. Total Market size of GAD in Japan
18.12.2. Total Market Size of GAD by Therapies in Japan
19. Market Access and Reimbursement of GAD Therapies
19.1. NICE Recommendations
19.2. British Association of Psychopharmacology Recommendations
19.3. Access and Reimbursement of Other Therapies
19.4. Reimbursement Management
20. Market Drivers
21. Market Barriers
22. Appendix
22.1. Bibliography
22.2. Report Methodology
23. DelveInsight Capabilities
24. Disclaimer
25. About DelveInsight
Table 1 Summary of GAD Market, Epidemiology, and Key Events (2017–2030)
Table 2 “Normal” Worry vs. Generalized Anxiety Disorder
Table 3 Medical Conditions and Medications that Can Cause Anxiety
Table 4 Characteristics to define GAD in DSM-V
Table 5 Evolution of the definition of GAD in succeeding editions of the DSM and ICD
Table 6 Total 12-Month Prevalent Cases of GAD in the 7MM (2017–2030)
Table 7 Total 12-Month Prevalent Cases of GAD in the United States (2017–2030)
Table 8 Gender-Specific Cases of GAD in the United States (2017–2030)
Table 9 Age-Specific Cases of GAD in the United States (2017–2030)
Table 10 Severity-Specific Cases of GAD in Children and Adolescents in the United States (2017–2030)
Table 11 Severity-Specific Cases of GAD in Adults in the United States (2017–2030)
Table 12 Total 12-Month Prevalent Cases of GAD in Germany (2017–2030)
Table 13 Gender-Specific Cases of GAD in Germany (2017–2030)
Table 14 Age-Specific Cases of GAD in Germany (2017–2030)
Table 15 Severity-Specific Cases of GAD in Children and Adolescents in Germany (2017–2030)
Table 16 Severity-Specific Cases of GAD in Adults in Germany (2017–2030)
Table 17 Total 12-Month Prevalent Cases of GAD in France (2017–2030)
Table 18 Gender-Specific Cases of GAD in France (2017–2030)
Table 19 Age-Specific Cases of GAD in France (2017–2030)
Table 20 Severity-Specific Cases of GAD in Children and Adolescents in France (2017–2030)
Table 21 Severity-Specific Cases of GAD in Adults in France (2017–2030)
Table 22 Total 12-Month Prevalent Cases of GAD in Italy (2017–2030)
Table 23 Gender-Specific Cases of GAD in Italy (2017–2030)
Table 24 Age-Specific Cases of GAD in Italy (2017–2030)
Table 25 Severity-Specific Cases of GAD in Children and Adolescents in Italy (2017–2030)
Table 26 Severity-Specific Cases of GAD in Adults in Italy (2017–2030)
Table 27 Total 12-Month Prevalent Cases of GAD in Spain (2017–2030)
Table 28 Gender-Specific Cases of GAD in Spain (2017–2030)
Table 29 Age-Specific Cases of GAD in Spain (2017–2030)
Table 30 Severity-Specific Cases of GAD in Children and Adolescents in Spain (2017–2030)
Table 31 Severity-Specific Cases of GAD in Adults in Spain (2017–2030)
Table 32 Total 12-Month Prevalent Cases of GAD in the UK (2017–2030)
Table 33 Gender-Specific Cases of GAD in the UK (2017–2030)
Table 34 Age-Specific Cases of GAD in the UK (2017–2030)
Table 35 Severity-Specific Cases of GAD in Children and Adolescents in the UK (2017–2030)
Table 36 Severity-Specific Cases of GAD in Adults in the UK (2017–2030)
Table 37 Total 12-Month Prevalent Cases of GAD in Japan (2017–2030)
Table 38 Gender-Specific Cases of GAD in Japan (2017–2030)
Table 39 Age-Specific Cases of GAD in Japan (2017–2030)
Table 40 Severity-Specific Cases of GAD in Children and Adolescents in Japan (2017–2030)
Table 41 Severity-Specific Cases of GAD in Adults in Japan (2017–2030)
Table 42 Botanicals and Supplements Sometimes Used to Treat GAD and Panic Disorder
Table 43 Treatment Approach to GAD
Table 44 Treatment Recommendations Summary
Table 45 Marketed Drugs Analysis- Key cross
Table 46 Emerging Drugs Analysis-Key therapies
Table 47 Intuniv, Clinical Trial Description, 2020
Table 48 Troriluzole, Clinical Trial Description, 2020
Table 49 7MM Market Size of GAD, in USD Million (2017–2030)
Table 50 Total Market Size of GAD by Therapies in 7MM in USD Million (2017-2030)
Table 51 Total Market Size of GAD in the US, in USD Million (2017–2030)
Table 52 Total Market Size of GAD by Therapies in the US in USD Million (2017-2030)
Table 53 Total Market Size of GAD in Germany, in USD Million (2017–2030)
Table 54 Total Market Size of GAD by Therapies in Germany in USD Million (2017-2030)
Table 55 Total Market Size of GAD in France, in USD Million (2017–2030)
Table 56 Total Market Size of GAD by Therapies in France, in USD Million (2017-2030)
Table 57 Total Market Size of GAD in Italy, in USD Million (2017–2030)
Table 58 Total Market Size of GAD by Therapies in Italy in USD Million (2017-2030)
Table 59 Total Market Size of GAD in Spain, in USD Million (2017–2030)
Table 60 Total Market Size of GAD by Therapies in Spain in USD Million (2017-2030)
Table 61 Total Market Size of GAD in the UK, in USD Million (2017–2030)
Table 62 Total Market Size of GAD by Therapies in the UK in USD Million (2017-2030)
Table 63 Total Market Size of GAD in Japan, in USD Million (2017–2030)
Table 64 Total Market Size of GAD by Therapies in Japan in USD Million (2017-2030)
Figure 1 GAD SWOT Analysis
Figure 2 Epidemiology and Market Methodology
Figure 3 Overview of GAD
Figure 4 Symptoms and Behaviors Associated with Generalized Anxiety Disorder
Figure 5 Etiology of GAD
Figure 6 Risk factors for GAD
Figure 7 Mental Disorders Screening—General Anxiety Disorder Assessment (GAD-7)
Figure 8 Mental Disorders Screening—Generalized Anxiety Disorder 2-item (GAD-2)
Figure 9 Total 12-Month Prevalent Cases of GAD in the 7MM (2017–2030)
Figure 10 Total 12-Month Prevalent Cases of GAD in the United States (2017–2030)
Figure 11 Gender-Specific Cases of GAD in the United States (2017–2030)
Figure 12 Age-Specific Cases of GAD in the United States (2017–2030)
Figure 13 Severity-Specific Cases of GAD in Children and Adolescents in the United States (2017–2030)
Figure 14 Severity-Specific Cases of GAD in Adults in the United States (2017–2030)
Figure 15 Total 12-Month Prevalent Cases of GAD in Germany (2017–2030)
Figure 16 Gender-Specific Cases of GAD in Germany (2017–2030)
Figure 17 Age-Specific Cases of GAD in Germany (2017–2030)
Figure 18 Severity-Specific Cases of GAD in Children and Adolescents in Germany (2017–2030)
Figure 19 Severity-Specific Cases of GAD in Adults in Germany (2017–2030)
Figure 20 Total 12-Month Prevalent Cases of GAD in France (2017–2030)
Figure 21 Gender-Specific Cases of GAD in France (2017–2030)
Figure 22 Age-Specific Cases of GAD in France (2017–2030)
Figure 23 Severity-Specific Cases of GAD in Children and Adolescents in France (2017–2030)
Figure 24 Severity-Specific Cases of GAD in Adults in France (2017–2030)
Figure 25 Total 12-Month Prevalent Cases of GAD in Italy (2017–2030)
Figure 26 Gender-Specific Cases of GAD in Italy (2017–2030)
Figure 27 Age-Specific Cases of GAD in Italy (2017–2030)
Figure 28 Severity-Specific Cases of GAD in Children and Adolescents in Italy (2017–2030)
Figure 29 Severity-Specific Cases of GAD in Adults in Italy (2017–2030)
Figure 30 Total 12-Month Prevalent Cases of GAD in Spain (2017–2030)
Figure 31 Gender-Specific Cases of GAD in Spain (2017–2030)
Figure 32 Age-Specific Cases of GAD in Spain (2017–2030)
Figure 33 Severity-Specific Cases of GAD in Children and Adolescents in Spain (2017–2030)
Figure 34 Severity-Specific Cases of GAD in Adults in Spain (2017–2030)
Figure 35 Total 12-Month Prevalent Cases of GAD in the UK (2017–2030)
Figure 36 Gender-Specific Cases of GAD in the UK (2017–2030)
Figure 37 Age-Specific Cases of GAD in the UK (2017–2030)
Figure 38 Severity-Specific Cases of GAD in Children and Adolescents in the UK (2017–2030)
Figure 39 Severity-Specific Cases of GAD in Adults in the UK (2017–2030)
Figure 40 Total 12-Month Prevalent Cases of GAD in Japan (2017–2030)
Figure 41 Gender-Specific Cases of GAD in Japan (2017–2030)
Figure 42 Age-Specific Cases of GAD in Japan (2017–2030)
Figure 43 Severity-Specific Cases of GAD in Children and Adolescents in Japan (2017–2030)
Figure 44 Severity-Specific Cases of GAD in Adults in Japan (2017–2030)
Figure 45 GAD Treatment Flow chart
Figure 46 Cognitive Behavioural Therapy
Figure 47 Pharmacotherapy for GAD
Figure 48 GAD Management overview
Figure 49 Unmet Needs for Generalized anxiety disorder
Figure 50 Total Market Size of GAD in 7MM in USD Million (2017-2030)
Figure 51 Total Market Size of GAD by Therapies in 7MM in USD Million (2017-2030)
Figure 52 Market size of GAD in the US (2017–2030)
Figure 53 Total Market Size of GAD by Therapies in the US, in USD Million (2017-2030)
Figure 54 Market size of GAD in Germany (2017–2030)
Figure 55 Total Market Size of GAD by Therapies in Germany, in USD Million (2017-2030)
Figure 56 Market size of GAD in France (2017–2030)
Figure 57 Total Market Size of GAD by Therapies in France, in USD Million (2017-2030)
Figure 58 Market size of GAD in Italy (2017–2030)
Figure 59 Total Market Size of GAD by Therapies in Italy, in USD Million (2017-2030)
Figure 60 Market size of GAD in Spain (2017–2030)
Figure 61 Total Market Size of GAD by Therapies in Spain, in USD Million (2017-2030)
Figure 62 Market size of GAD in the UK (2017–2030)
Figure 63 Total Market Size of GAD by Therapies in the UK, in USD Million (2017-2030)
Figure 64 Market size of GAD in Japan (2017–2030)
Figure 65 Total Market Size of GAD by Therapies in Japan, in USD Million (2017-2030)
Figure 66 Market Drivers of GAD
Figure 67 Market Barriers to GAD

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook